Health TrialsbyHealthPanel

The Effect of Alogliptin Combined With Actoplus Met on Glucose and Lipid Metabolism and Pancreatic Function in Patients With T2DM Complicated With MAFLD

ConditionsT2DMMAFLD
Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-75
SponsorThe Fourth Affiliated Hospital of Zhejiang University School of Medicine

About this trial

To compare the efficacy and safety of the combination of alogliptin and actoplus met with that of actoplus met alone in improving the glucose and lipid metabolism and pancreatic function in T2DM patients complicated with MAFLD.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Clinical diagnosis of T2DM

Clinical diagnosis of MAFLD

HbA1c: 6.5-9.5%

BMI: 19-35 kg/m2

Disqualifiers

Severe infections, surgeries and other emergency

Other types of diabetes

Severe cardiovascular, brain, liver and kidney disorders

Malignant tumor

Trial design

Design model

Parallel

Treatments tested in this trial

  • alogliptin and actoplus met

    Drug

    combination of alogliptin and actoplus met

  • actoplus met

    Drug

    actoplus met

Treatment groups

80 Participants
are divided into 2 treatment groups
Group A: alogliptin and actoplus metExperimental treatment 1 intervention
Group B: actoplus metActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

hemoglobin A1c

Time frame
6 months of treatment

Secondary outcomes

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

The Fourth Affiliated Hospital of Zhejiang University School of Medicine

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: